ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO755

Effects of Medium Cut-Off (Theranova) Dialyzer on Hemodialysis Patients: A Prospective, Cross-Over Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Cozzolino, Mario, Department of Health Sciences, University of Milan, Milan, Italy

Recent data suggest that expanded hemodialysis (HDx) enabled by middle cut-off membrane promotes greater clearance for large middle molecules implicated in inflammation and immune function modulation.


In prospective, open-label, controlled, crossover pilot study, 20 prevalent hemodialysis (HD) patients were studied for 6 months in two dialysis treatments as follows: one MCO (Theranova) dialyzer and one high-flux dialyzer.


In table 1, we present the baseline characteristics of HD patients. Hemoglobin, ferritin, transferrin, calcium, phosphate, parathyroid hormone and 25(OH) vitamin D levels were similar with MCO and high-flux HD. In addition, we did not find any albumin loss in the two treatment groups. Also, dialysis adequacy was similar in MCO and high-flux HD treated patients. Interestingly, the cumulative number of episodes of infection, confirmed clinically and treated with antibiotics) was significantly lower in HDx (# 6), compared with high-flux HD patients (# 20) (Figure 1), while number of hospitalizations did not change.


In conclusion, our pilot study demonstrates that Theranova dialyzer has a good tolerance profile and, intriguingly, reduces the cumulative number of infections in HD patients.


  • Commercial Support